Your browser doesn't support javascript.
loading
Mesenchymal stem cell therapy in eosinophilic granulomatosis with polyangiitis-related lower limb gangrene: a case report.
Wang, Hui; Zhang, Qian; Wu, Sensen; Pan, Dikang; Ning, Yachan; Wang, Cong; Guo, Jianming; Gu, Yongquan.
Afiliación
  • Wang H; Department of Vascular Surgery, Xuanwu Hospital, Capital Medical University, No. 45, Changchun Street, Beijing, 100053, China.
  • Zhang Q; ShangRao Jingkai Health-Biotech United Hospital, ShangRao, 334000, Jiangxi, China.
  • Wu S; ShangRao Jingkai Health-Biotech United Hospital, ShangRao, 334000, Jiangxi, China.
  • Pan D; Shangrao Normal University, ShangRao, 334000, Jiangxi, China.
  • Ning Y; Department of Vascular Surgery, Xuanwu Hospital, Capital Medical University, No. 45, Changchun Street, Beijing, 100053, China.
  • Wang C; Department of Vascular Surgery, Xuanwu Hospital, Capital Medical University, No. 45, Changchun Street, Beijing, 100053, China.
  • Guo J; Department of Vascular Surgery, Xuanwu Hospital, Capital Medical University, No. 45, Changchun Street, Beijing, 100053, China.
  • Gu Y; Department of Vascular Surgery, Xuanwu Hospital, Capital Medical University, No. 45, Changchun Street, Beijing, 100053, China.
Stem Cell Res Ther ; 15(1): 307, 2024 Sep 16.
Article en En | MEDLINE | ID: mdl-39285456
ABSTRACT

BACKGROUND:

Eosinophilic granulomatosis with polyangiitis (EGPA), a rare but life-threatening systemic vasculitis, is distinguished by marked eosinophilia and presents with diverse symptoms, including asthma, cutaneous purpura, ecchymosis, skin necrosis, cardiac lesions, peripheral neuropathy, and necrotizing vasculitis. The etiology of EGPA involves a complex interaction among humoral, adaptive, innate, and allergic immune responses. Standard treatment employs prolonged high-dose glucocorticoid therapy, which is critical for survival; however, some patients' symptoms cannot be relieved. CASE REPORT This case report details the medical management of an 11-year-old patient with EGPA, who was at risk of bilateral lower limb amputation due to differential arterial occlusion and severe, necrotizing vasculitis-induced gangrene in both feet. Treatment modalities administered included systemic infusion of Umbilical Cord Mesenchymal Stem Cells (UC-MSCs), targeted gastrocnemius muscle injections, and application of a Placenta-Derived Mesenchymal Stem Cells (PD-MSCs) hydrogel.

RESULTS:

After receiving a four-month regimen of allogeneic mesenchymal stem cell therapy via intravenous and local administration, the patient showed normalized eosinophil counts, reestablished blood flow in the dorsal arteries, and marked improvement in foot ulcerations.

CONCLUSION:

Mesenchymal stem cell therapy is a promising option for severe EGPA cases refractory to glucocorticoids.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Granulomatosis con Poliangitis / Extremidad Inferior / Trasplante de Células Madre Mesenquimatosas / Gangrena Límite: Child / Female / Humans / Male Idioma: En Revista: Stem Cell Res Ther Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Granulomatosis con Poliangitis / Extremidad Inferior / Trasplante de Células Madre Mesenquimatosas / Gangrena Límite: Child / Female / Humans / Male Idioma: En Revista: Stem Cell Res Ther Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: Reino Unido